Oral administration of CXCL12-expressing Limosilactobacillus reuteri improves colitis by local immunomodulatory actions in preclinical models.
Öhnstedt E, Doñas C, Parv K, Pang Y, Lofton Tomenius H, Carrasco López M, Gannavarapu VR, Choi J, Ovezik M, Frank P, Jorvid M, Roos S, Vågesjö E, Phillipson M.
Öhnstedt E, et al. Among authors: choi j.
Am J Physiol Gastrointest Liver Physiol. 2024 May 23. doi: 10.1152/ajpgi.00022.2024. Online ahead of print.
Am J Physiol Gastrointest Liver Physiol. 2024.
PMID: 38780469